Չեխիա - չեխերեն - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi ab, uppsala array - 1354 ČiŠtĚnÝ sÓjovÝ olej; 4090 triacylglyceroly se stŘednÍm ŘetĚzcem; 15999 ČiŠtĚnÝ olivovÝ olej; 17839 rybÍ olej bohatÝ na omega-3-kyseliny - infuzní emulze - tukovÉ emulze

Եվրոպական Միություն - չեխերեն - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologické látky - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Եվրոպական Միություն - չեխերեն - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - imunitní séra a imunoglobuliny, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Եվրոպական Միություն - չեխերեն - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologické látky - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Եվրոպական Միություն - չեխերեն - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologické látky - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Չեխիա - չեխերեն - SUKL (Státní ústav pro kontrolu léčiv)

almirall hermal gmbh, reinbek array - 552 erythromycin - mast - 20mg/g - erythromycin

Չեխիա - չեխերեն - SUKL (Státní ústav pro kontrolu léčiv)

sanofi pasteur, lyon array - 13899 inaktivovanÝ virus hepatitidy a - injekční suspenze v předplněné injekční stříkačce - 160eu - hepatitida a, inaktivovanÝ celÝ virus

Չեխիա - չեխերեն - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 7653 buprenorfin - transdermální náplast - 35mcg/h - buprenorfin

Չեխիա - չեխերեն - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 7653 buprenorfin - transdermální náplast - 52,5mcg/h - buprenorfin

Չեխիա - չեխերեն - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 7653 buprenorfin - transdermální náplast - 70mcg/h - buprenorfin